Figure 3

Involvement of MCM7 in the proliferation of lung and bladder cancer cells. (A) Knockdown effects of siRNAs targeting MCM7 on cancer cells. Top, western blot analysis of MCM7 in A549, SBC5 and SW780 cells after treatment with two MCM7 siRNAs (siMCM7#1 and siMCM7#2) and two control siRNAs (siEGFP and siNC). ACTB was used as an internal control. Middle, immunocytochemical analysis of MCM7 in A549 and SBC5 cells after treatment with siRNAs. The nucleus was stained with DAPI, and the incorporation of 5-bromo-2'-deoxyuridine (BrdU) into replicating DNA was used to label proliferating cells. Bottom, effects of MCM7 knockdown on the viability of lung and bladder cancer cell lines (A549, SBC5 and SW780). The viability of cancer cells was measured by Cell Counting Kit-8, and statistical analysis was done using Student's t-test. *, P < 0.05. (B) Effects of MCM7 siRNAs on the growth of HFL-1 cells and CCD-18Co cells. The viability of the cells was measured by Cell Counting Kit-8, and statistical analysis was done using Student's t-test. NS, not significant. (C) Effects of heliquinomycin on the viability of normal and cancer cells. Left, the cell vitality assay was performed using Cell Counting Kit-8 after treatment with heliquinomycin for 72 h. Results are the mean ± SD of three independent experiments. Right, the cell viability of A549, SBC5, SW780 and HFL-1 72 h after treatment with 4.0 μM heloquinomycin.